GLSIGreenwich LifeSciences, Inc.Signing up patients
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 2,250 (planned)
- Started
- Dec 16, 2022
- Main results expected
- Dec 2031
- Fully finished
- Dec 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Invasive Breast Cancer-free Survival (IBCFS)
Measured over: Median 4 years of follow-up (interim analyses planned)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05232916 · record last updated 2026-08-06 · checked 2026-11-09 15:42 UTC